Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Resource Type
Article
Authors
Livingstone, Elisabeth ; Zimmer, Lisa ; Hassel, Jessica C ; Fluck, Michael ; Eigentler, Thomas K ; Loquai, Carmen ; Haferkamp, Sebastian ; Gutzmer, Ralf ; Meier, Friedegund ; Mohr, Peter ; Hauschild, Axel ; Schilling, Bastian ; Menzer, Christian ; Kiecker, Felix ; Dippel, Edgar ; Roesch, Alexander ; Ziemer, Mirjana ; Conrad, Beate ; Körner, Silvia ; Simon, Jan-Christoph ; Herbst, Rudolf A ; Berking, Carola ; Utikal, Jochen ; Sell, Sabine ; Martens, Uwe M ; Terheyden, Patrick ; Stadler, Rudolf ; Windemuth-Kieselbach, Christine ; Schwarz, Leonora ; Garbe, Claus ; Becker, Jürgen C ; Schadendorf, Dirk
Source
In The Lancet 1-7 October 2022 400(10358):1117-1129
Subject
Primary Research Articles
Language
ISSN
0140-6736